The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells

Abstract

BackgroundIn the present study we determined the relative contribution of two processes to breast cancer progression: (1) Intrinsic events, such as activation of the Ras pathway and down-regulation of p53; (2) The inflammatory cytokines TNFα and IL-1β, shown in our published studies to be highly expressed in tumors of >80% of breast cancer patients with recurrent disease.MethodsUsing MCF-7 human breast tumor cells originally expressing WT-Ras and WT-p53, we determined the impact of the above-mentioned elements and cooperativity between them on the expression of CXCL8 (ELISA, qRT-PCR), a member of a “cancer-related chemokine cluster” that we have previously identified. Then, we determined the mechanisms involved (Ras-binding-domain assays, Western blot, luciferase), and tested the impact of Ras + TNFα on angiogenicity (chorioallantoic membrane assays) and on tumor growth at the mammary fat pad of mice and on metastasis, in vivo.ResultsUsing RasG12V that recapitulates multiple stimulations induced by receptor tyrosine kinases, we found that RasG12V alone induced CXCL8 expression at the mRNA and protein levels, whereas down-regulation of p53 did not. TNFα and IL-1β potently induced CXCL8 expression and synergized with RasG12V, together leading to amplified CXCL8 expression. Testing the impact of WT-Ras, which is the common form in breast cancer patients, we found that WT-Ras was not active in promoting CXCL8; however, TNFα has induced the activation of WT-Ras: joining these two elements has led to cooperative induction of CXCL8 expression, via the activation of MEK, NF-κB and AP-1. Importantly, TNFα has led to increased expression of WT-Ras in an active GTP-bound form, with properties similar to those of RasG12V. Jointly, TNFα + Ras activities have given rise to increased angiogenesis and to elevated tumor cell dissemination to lymph nodes.ConclusionsTNFα cooperates with Ras in promoting the metastatic phenotype of MCF-7 breast tumor cells, and turns WT-Ras into a tumor-supporting entity. Thus, in breast cancer patients the cytokine may rescue the pro-cancerous potential of WT-Ras, and together these two elements may lead to a more aggressive disease. These findings have clinical relevance, suggesting that we need to consider new therapeutic regimens that inhibit Ras and TNFα, in breast cancer patients.

Co-Inflammatory Roles of TGFβ1 in the Presence of TNFα Drive a Pro-inflammatory Fate in Mesenchymal Stem Cells

“…TNFα concentration was selected based on our previous studies (40–43), as well as other cell systems (e.g., Ref. 44–46).…”

Dynamic aberrant NF-κB spurs tumorigenesis: A new model encompassing the microenvironment

“…As p53 interacts with RelA [71] dysregulation of the p53 network leads to the question if RelA targets are overexpressed in cancer [96], and which molecular mechanisms mediate their effects on the microenvironment [97]. We know that malignant cells secrete signaling molecules such as cytokines and metabolites to redirect the phenotype of cells in surrounding tissue [37,98,99]. and that diverse types of cancer can secrete signaling molecules that disrupt the immune responses [51,68]; interaction between cancer and stroma may allow a tumor escape rejection, even after being recognized by adaptive immunity [100].…”

Oncogenic Ras modulates p38 MAPK-mediated inflammatory cytokine production in glioblastoma cells

“…While the roles of Raf-MEK-Erk and PI3K-Akt signaling in Ras-driven tumorigenesis are well established, the signaling pathways underlying interactions between Ras and the microenvironment are still poorly understood. 22,29 Importantly, recent research revealed that oncogenes can signal via different pathways when exposed to the microenvironment. For example, EGFRvIII up-regulates IL-6 via the PI3K-Smad5-ID3 pathway.…”